In this field, Fraunhofer IZI is working on a new technology platform which enables RNA molecules to be identified and ascertained for their potential to effect the intracellular control of signal processes. This provides indications for the development of new drugs. Furthermore, Fraunhofer IZI develops pharmacogenomic and protein-chemistry techniques for the identification of individual-specific differences from which particular disease susceptibility, sensitivity to certain methods of therapy and even the course of disease can be predicted.